- Walgreens expanding scope of retail pharmacy experience and services heading into fiscal 2014
- ROUNDTABLE: Pharmacy’s future in sync with technology
- Bloomberg: Greg Wasson joins thought leaders to discuss the state of health care in the United States
- CVS' Merlo: Health reform to benefit business in 2014
- CVS Caremark's 'ability' and 'agility' a key focus of 2013 Analyst Day
NEW YORK — Teva Pharmaceutical Industries has transferred its stock listing from NASDAQ to the New York Stock Exchange, the drug maker said Wednesday.
The company began trading on the NYSE under the ticker symbol "TEVA." On hand Wednesday to ring the Opening Bell and celebrate the company's first day of trading on NYSE were Teva's new president and CEO Jeremy Levin, as well as board chairman Phillip Frost, CFO Eyal Desheh, Teva Americas CEO William Marth and employees from Teva's businesses around the world.
“We are pleased to partner with the NYSE and begin using their state of the art trading platform and market research,” Frost said. “We are joining a network of true innovators and leaders listed on the NYSE.”
Teva said it is the second-largest company to transfer its stock listing to the NYSE from NASDAQ.